UK-based rare diseases specialist Mereo BioPharma (LON: MPH) was trading 19% higher as Monday’s trading neared its conclusion.
The company’s licensing agreement with Sino-American biotech Oncologie was announced that day, a deal that could earn Mereo more than $300 million if all goes to plan.
This global license agreement is for the development and commercialization of navicixizumab, an anti-DLL4/VEGF bispecific antibody currently being evaluated in an ongoing Phase Ib study in combination with paclitaxel in patients with advanced heavily pre-treated ovarian cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze